The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Videos  >  

Rationale for Combining Atezolizumab/Bevacizumab in mRCC

Brian I. Rini, MD
Published Online:7:02 PM, Mon July 16, 2018


Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with metastatic renal cell carcinoma (mRCC) in the IMmotion151trial.

Both of these agents have proven to be active as monotherapies, and as such, it seemed rational to combine them. Additionally, VEGF has immune-suppressive effects, including promoting myeloid-derived suppressor cells, regulatory T cells, etc. By suppressing VEGF, the microenvironment is more favorable for the immunotherapy to act.

Rini says it is very clear that there is substantial activity seen in combining these 2 types of agents in patients with mRCC.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.